Perioperative Management of Ulcerative Colitis: A Systematic Review

Overview

Journal Dis Colon Rectum

Specialty Gastroenterology

Date 2022 Aug 25

PMID 36007165

Authors

Kate E Lee

Adam S Faye

Severine Vermeire

Bo Shen

Affiliations

Soon will be listed here.

Abstract

Background: Patients with ulcerative colitis may require colectomy for severe disease unresponsive or refractory to pharmacological therapy. Managing ulcerative colitis is complicated because there are many factors at play, including patient optimization and treatment, as the guidance varies on the ideal perioperative use of corticosteroids, immunomodulators, biologics, and small molecule agents.

Objective: A systematic literature review was performed to describe the current status of perioperative management of ulcerative colitis.

Data Sources: PubMed and Cochrane databases were used.

Study Selection: Studies published between January 2000 and January 2022, in any language, were included. Articles regarding pediatric or endoscopic management were excluded.

Interventions: Perioperative management of ulcerative colitis was included.

Main Outcome Measures: Successful management, including reducing surgical complication rates, was measured.

Results: A total of 121 studies were included in this review, including 23 meta-analyses or systematic reviews, 25 reviews, and 51 cohort studies.

Limitations: Qualitative review including all study types. The varied nature of study types precludes quantitative comparison.

Conclusion: Indications for colectomy in ulcerative colitis include severe disease unresponsive to medical treatment and colitis-associated neoplasia. Urgent colectomy has a higher mortality rate than elective colectomy. Corticosteroids are associated with postsurgical infectious complications and should be stopped or weaned before surgery. Biologics are not associated with adverse postoperative effects and do not necessarily need to be stopped preoperatively. Additionally, the clinician must assess individuals' comorbidities, nutrition status, and risk of venous thromboembolism. Nutritional imbalance should be corrected, ideally at the preoperative period. Postoperatively, corticosteroids can be tapered on the basis of the length of preoperative corticosteroid use.

Citing Articles

Transanal ileal pouch-anal anastomosis: A systematic review and meta-analysis of technical approaches and clinical outcomes.

Stephens I, Byrnes K, Burke J Langenbecks Arch Surg. 2024; 409(1):153.

PMID: 38705912 PMC: 11070401. DOI: 10.1007/s00423-024-03343-7.

A Case of Ulcerative Colitis Induced by Paraneoplastic Syndrome?.

Zhang T, Pan Z, Tong W, Zhou Y, Cheng Y, Jin D J Inflamm Res. 2023; 16:3319-3327.

PMID: 37576158 PMC: 10422985. DOI: 10.2147/JIR.S418733.

Association between body fat composition and disease duration, clinical activity, and intravenous corticosteroid-induced response in inflammatory bowel disease.

He S, Huang Y, Peng Y, Chai J, Chen K Lipids Health Dis. 2023; 22(1):106.

PMID: 37481662 PMC: 10363311. DOI: 10.1186/s12944-023-01874-4.

References

Turner D, Walsh C, Steinhart A, Griffiths A . Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2006; 5(1):103-10. DOI: 10.1016/j.cgh.2006.09.033. View

Wong D, Roth E, Feuerstein J, Poylin V . Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019; 7(2):77-90. PMC: 6454839. DOI: 10.1093/gastro/goz004. View

Fleming F, Gaertner W, Ternent C, Finlayson E, Herzig D, Paquette I . The American Society of Colon and Rectal Surgeons Clinical Practice Guideline for the Prevention of Venous Thromboembolic Disease in Colorectal Surgery. Dis Colon Rectum. 2017; 61(1):14-20. DOI: 10.1097/DCR.0000000000000982. View

Spinelli A, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V . ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. J Crohns Colitis. 2021; 16(2):179-189. DOI: 10.1093/ecco-jcc/jjab177. View

Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D . Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol. 2010; 8(7):591-9.e1. DOI: 10.1016/j.cgh.2010.01.016. View

Yang Z, Hong L, Wu Q, Wu K, Fan D . Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis. Int J Surg. 2014; 12(3):224-30. DOI: 10.1016/j.ijsu.2013.12.015. View

Herfarth H . Anti-tumor necrosis factor therapy to prevent Crohn's disease recurrence after surgery. Clin Gastroenterol Hepatol. 2014; 12(9):1503-6. DOI: 10.1016/j.cgh.2014.02.014. View

Satsangi J, Silverberg M, Vermeire S, Colombel J . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6):749-53. PMC: 1856208. DOI: 10.1136/gut.2005.082909. View

Bitton A, Buie D, Enns R, Feagan B, Jones J, Marshall J . Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2011; 107(2):179-94. DOI: 10.1038/ajg.2011.386. View

10.

Lopez-Sanroman A . Steroids and Postoperative Complications in IBD. Curr Drug Targets. 2019; 20(13):1323-1326. DOI: 10.2174/1389450120666190320122939. View

11.

Burr N, Gracie D, Black C, Ford A . Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2021; . DOI: 10.1136/gutjnl-2021-326390. View

12.

Randall J, Singh B, Warren B, Travis S, Mortensen N, George B . Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010; 97(3):404-9. DOI: 10.1002/bjs.6874. View

13.

Patel S, Patel M, Goldfarb M, Ortega A, Ault G, Kaiser A . Elective versus emergency surgery for ulcerative colitis: a National Surgical Quality Improvement Program analysis. Am J Surg. 2013; 205(3):333-7. DOI: 10.1016/j.amjsurg.2012.10.014. View

14.

Sandborn W, Van Assche G, Reinisch W, Colombel J, DHaens G, Wolf D . Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2011; 142(2):257-65.e1-3. DOI: 10.1053/j.gastro.2011.10.032. View

15.

Bregnbak D, Mortensen C, Bendtsen F . Infliximab and complications after colectomy in patients with ulcerative colitis. J Crohns Colitis. 2012; 6(3):281-6. DOI: 10.1016/j.crohns.2011.08.014. View

16.

Sahami S, Bartels S, dHoore A, Fadok T, Tanis P, Lindeboom R . A Multicentre Evaluation of Risk Factors for Anastomotic Leakage After Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease. J Crohns Colitis. 2015; 10(7):773-8. DOI: 10.1093/ecco-jcc/jjv170. View

17.

Singh S, Fumery M, Sandborn W, Murad M . Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2017; 47(2):162-175. DOI: 10.1111/apt.14422. View

18.

Bernstein C, Fried M, Krabshuis J, Cohen H, Eliakim R, Fedail S . World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2009; 16(1):112-24. DOI: 10.1002/ibd.21048. View

19.

Zittan E, Milgrom R, Ma G, Wong-Chong N, OConnor B, McLeod R . Preoperative Anti-tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After Ileal Pouch-anal Anastomosis. Inflamm Bowel Dis. 2016; 22(10):2442-7. DOI: 10.1097/MIB.0000000000000919. View

20.

Mohammed Vashist N, Samaan M, Mosli M, Parker C, MacDonald J, Nelson S . Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2018; 1:CD011450. PMC: 6491285. DOI: 10.1002/14651858.CD011450.pub2. View